The stock's rise snapped a three-day losing streak.

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron ... performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within ...

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.

Regeneron prioritizes returning capital to shareholders. Regeneron's issues in the past year are ... despite the Eylea franchise's unimpressive performance in the fourth quarter, Regeneron's ...